

Discloser Identifier: 435827

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Astellas Pharma Canada	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory board <i>Additional Information:</i>		
AstraZeneca Canada	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory board <i>Additional Information:</i>		
Bayer	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory board <i>Additional Information:</i>		
Bristol-Myers Squibb Canada	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory board <i>Additional Information:</i>		
Hoffmann-La Roche Limited	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory board <i>Additional Information:</i>		
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory board <i>Additional Information:</i>		
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory board <i>Additional Information:</i>		
Taiho Pharmaceutical	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory board <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 808781

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AB Science	Grant / Contract	Other - Clinical study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Adaptimmune	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Advenchen	Grant / Contract	Other - Clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Ayala Pharma	Grant / Contract	Other - Clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bavarian Nordic A/S	Grant / Contract	Other - Clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bayer HealthCare Pharmaceuticals Inc.	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Blueprint Medicines Corporation	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Boehringer Ingelheim	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Entity	Type	Interest Held By
BTG pharma	Grant / Contract	Other - Clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
C4 Therapeutics	Grant / Contract	Other - study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> study support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
CBA pharma	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Daiichi Sankyo Inc.	Grant / Contract	Other - study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> study support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Deciphera Pharmaceuticals Inc.	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Desmoid Tumor Research Foundation	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Eli Lilly and Company	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Epizyme, Inc.,	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> <i>Grant / Contract Purpose:</i> Research
Forma Pharma	Grant / Contract	Other - Clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Genmab	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
GlaxoSmithKline, LLC.	Grant / Contract	Other - Clinical trial support

Entity	Type	Interest Held By
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		
Gradilis	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Incyte Corporation	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
InhibRx	Grant / Contract	Other - study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> study support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Karyopharm Therapeutics Inc.	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Merck	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Monopar Pharma	Grant / Contract	Other - Study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> study support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Novartis	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Noxopharm	Grant / Contract	Other - study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> study support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Philogen	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
PTC pharma	Grant / Contract	Other - Clinical trial support

Entity	Type	Interest Held By
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Rain Therapeutics	Grant / Contract	Other - study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> study support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Salarius Pharma	Grant / Contract	Other - Study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Study support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Springworks	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Takeda Oncology	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Theseus Pharma	Grant / Contract	Other - study support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> study support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
TRACON Pharma	Grant / Contract	Other - clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Trillium Pharma	Grant / Contract	Other - Clinical trial support
<i>Recipient Name:</i> Mayo Clinic <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

"Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)"

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Howard Bailey

Discloser Identifier: 1087983

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Charlotte Benson

Discloser Identifier: 931641

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Nam Bui

Discloser Identifier: 867731

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Rain Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory Board <i>Additional Information:</i> Advisory Board Meeting, 2 hours		
SpringWorks	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory Board <i>Additional Information:</i> Advisory Board, 3 hours		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)" to the New England Journal of Medicine

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Melissa Burgess

Discloser Identifier: 1014116

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, A Gamma Secretase Inhibitor for treatment of Desmoid Tumors: a multicenter, randomised versus placebo, phase 3 trial (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

John Charlson

Discloser Identifier: 1087959

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
ayala	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> DSMB member <i>Additional Information:</i>		
Deciphera Pharmaceuticals Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant <i>Additional Information:</i>		
springworks	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory Board <i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 854083

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Aadi Bioscience	Stock	Self
<i>Additional Information:</i>		
Cellestia Biotech AG	Stock	Self
<i>Additional Information:</i>		
Counterpoint Biomedica LLC	Stock	Self
<i>Additional Information:</i>		
IMMIX Biopharma	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 402749

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AADi	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> Clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Advenchen	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i>
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
AstraZeneca Pharmaceuticals LP	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Ayala	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i>
Comprehensive Cancer Center, University of Michigan	Employment	Self
<i>Title:</i> Professor of Internal Medicine <i>Additional Information:</i>		<i>Position Description:</i>
Cornerstone Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Deciphera Pharmaceuticals Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Epizyme, Inc.,	Grant / Contract	Self

Entity	Type	Interest Held By
<p><i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i></p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i></p>		
Epizyme, Inc.,	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i></p>		
GlaxoSmithKline	Grant / Contract	Self
<p><i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i></p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
GlaxoSmithKline, LLC.	Grant / Contract	Self
<p><i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i></p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
Incyte Corporation	Grant / Contract	Self
<p><i>Recipient Name:</i> Regents at University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i></p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
Ipsen Biopharmaceuticals, Inc	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i></p>		
Janssen Biotech	Grant / Contract	Self
<p><i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i></p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
Jazz Pharmaceuticals	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i></p>		
Medivation Inc.	Grant / Contract	Self
<p><i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i></p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i></p>		
Mundipharma	Grant / Contract	Self
<p><i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i></p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
Novartis	Grant / Contract	Self

Entity	Type	Interest Held By
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i>		
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Plexikon Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Qilu Puget Sound	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i>		
Springworks	Grant / Contract	Self
<i>Recipient Name:</i> Regents of University of Michigan <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Intellectual Property

Type	Is Licensed	Interest Held By
Other Intellectual Property - Write electronic updates for UpToDate, Inc- onlin	-	Self
<i>Description:</i> Write electronic updates for UpToDate, Inc- online medical information resource <i>Type:</i> <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFI Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 524114

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bioatla	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> advisory board <i>Additional Information:</i>		
C4Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> advisory board <i>Additional Information:</i>		
Eisai	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> invited to discuss eribulin in vascular sarcomas <i>Additional Information:</i>		
Foghorn	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> advisory board <i>Additional Information:</i>		
Ikena	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> advisory board <i>Additional Information:</i>		
Massachusetts General Hospital	Employment	Self
<i>Title:</i> Assistant Professor of Medicine <i>Additional Information:</i>		<i>Position Description:</i> physician, hematology/oncology
PharmaMar	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> advisory board <i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Nirogacestat, a Gamma-Secretase Inhibitor for Desmoid Tumors

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 878321

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

"Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)"

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Lara Davis

Discloser Identifier: 509669

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Daichi Sankyo Company	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i> Pexidartinib Advisory Board member in August 2020 and December 2020. Workshop participant regarding pexidartinib dosing in March 2022.		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 754587

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Blueprint Medicines Corporation	Other	Self
<i>Category:</i> Other <i>Description:</i> Advisory board <i>Additional Information:</i> Virtual advisory board		
Daiichi Sankyo Company	Other	Self
<i>Category:</i> Other <i>Description:</i> Advisory Board <i>Additional Information:</i> 1 day advisory board meeting		
Deciphera Pharmaceuticals Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant in 2020 and 2021 for discussions about use of repriminib <i>Additional Information:</i> 4 virtual meetings a year for 1 hour each		
Exelixis	Other	Self
<i>Category:</i> Other <i>Description:</i> Advisory Boards <i>Additional Information:</i> Virtual Advisory Board		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, a Novel Gamma Secretase Inhibitor for Desmoid Tumors

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Palma Dileo

Discloser Identifier: 890249

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Deciphera Pharmaceuticals Inc.	Expert Witness	Self
<i>Category:</i> Expert Witness <i>Description:</i> Deciphera Advisory Board <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, a Novel Gamma Secretase Inhibitor for Desmoid Tumors

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Noah Federman

Discloser Identifier: 425671

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AYALA	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> <i>Additional Information:</i>		
Bayer	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaker Bureau <i>Additional Information:</i>		
genmab	Stock	Self
<i>Additional Information:</i>		
Tempus Labs	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat a novel gamma secretase inhibitor for desmoid tumors

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Hans Gelderblom

Discloser Identifier: 517367

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, : A Gamma Secretase Inhibitor for treatment of Desmoid Tumors: a multicenter, randomised versus placebo, phase 3 trial (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 682794

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Ayala	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Medical Advisory Board <i>Additional Information:</i>		
Bayer Healthcare	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Sorafenib in desmoid tumor <i>Additional Information:</i>		
Boehringer Ingelheim	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> MDM2 inhibitors in oncology <i>Additional Information:</i>		
Epizyme, Inc.,	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Tazemetstat in Epithelioid sarcoma <i>Additional Information:</i>		
Food and Drug Administration	Grant / Contract	Self
<i>Recipient Name:</i> Mrinal Gounder <i>Grant / Contract Description:</i> R01 FD005105 <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Karyopharm Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Selinexor in liposarcoma <i>Additional Information:</i>		
National Cancer Institute	Grant / Contract	Other - MSKCC
<i>Recipient Name:</i> MSKCC <i>Grant / Contract Description:</i> National Institutes of Health (P30CA008748 core grant (CCSG shared resources and core facility) <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Rain Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Medical Advisory Board <i>Additional Information:</i>		

Entity	Type	Interest Held By
Regeneron Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Medical Advisory Board <i>Additional Information:</i>		
Springworks Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Medical Advisory Board <i>Additional Information:</i>		

Intellectual Property

Type	Is Licensed	Interest Held By
Other Intellectual Property - GODDESS - Gounder/DTRF Desmoid Symptom/Impact Sca	-	Other - License held by MSKCC. License fees for commercial use is utilized towards research in desmoid tumors
<i>Description:</i> GODDESS - Gounder/DTRF Desmoid Symptom/Impact Scale <i>Additional Information:</i>		<i>Type:</i> Patient Reported Outcomes Questionnaire
Other Intellectual Property - UpToDate royalty	-	Self
<i>Description:</i> UpToDate royalty <i>Additional Information:</i>		<i>Type:</i> Honorarium

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Ravin Ratan, MD, M.Ed; Thierry Alcindor, MD, MSc; Patrick Schöffski, MD, MPH; Winette T. van der Graaf, MD, PhD; Breelyn A. Wilky, MD; Richard F. Riedel, MD; Allison Lim, PharmD; L. Mary Smith, PhD; Stephanie Moody, MS; Steven Attia, DO; Sant Chawla, MD, FRACP; Gina D'Amato, MD; Noah Federman, MD; Priscilla Merriam, MD; Brian A. Van Tine, MD, PhD; Bruno Vincenzi, PhD; Charlotte Benson, MBChB; Nam Quoc Bui, MD; Rashmi Chugh, MD; Gabriel Tinoco, MD; John Charlson, MD; Palma Dileo, MD; Lee Hartner, MD; Lore Lapeire, MD; Filomena Mazzeo, MD; Emanuela Palmerini, MD; Peter Reichardt, PhD; Silvia Stacchiotti, MD; Howard H. Bailey, MD; Melissa A. Burgess, MD; Gregory M. Cote, PhD; Lara E. Davis, MD; Hari Deshpande, MD; Hans Gelderblom, MD, PhD; Giovanni Grignani, MD; Elizabeth Loggers, MD, PhD, FAAHPM; Tony Philip, MD; Joseph G. Pressey, MD; Shivaani Kummar, MD, FACP;* Bernd Kasper, MD, PhD

Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 628891

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Grant / Contract	Self
<i>Recipient Name:</i> Giovanni Grignani <i>Grant / Contract Description:</i> Advisory Board <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Other - personal
GlaxoSmithKline	Grant / Contract	Self
<i>Recipient Name:</i> Giovanni Grignani <i>Grant / Contract Description:</i> Grant <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Giovanni Grignani <i>Grant / Contract Description:</i> Advisory board <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Other - personal
Novartis	Grant / Contract	Self
<i>Recipient Name:</i> Giovanni Grignani <i>Grant / Contract Description:</i> Advisory board <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Pharmamar	Grant / Contract	Self
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> Grant <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Nirogacestat, a Novel Gamma Secretase Inhibitor for Desmoid Tumors

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 1014453

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Amgen	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trial enrolled <i>Additional Information:</i>		
Eli Lilly and Company	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trial Enrolled <i>Additional Information:</i>		
Karyopharm Therapeutics Inc.	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trial Enroller <i>Additional Information:</i>		
Perelman School of Medicine, University of Pennsylvania	Employment	Self
<i>Title:</i> Clinical Associate Professor of Medicine <i>Additional Information:</i> <i>Position Description:</i> Hematologist/Oncologist in practice		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Bernd Kasper

Discloser Identifier: 1014477

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Ayala	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Springworks Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1087964

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Arxeon	Stock	Spouse/Partner
<i>Additional Information:</i>		
Bayer HealthCare Pharmaceuticals Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Boehringer Ingelheim	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
cadila	Consultant	Spouse/Partner
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Gilead Sciences Inc	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Harbour Biomed	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Mirati	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> <i>Additional Information:</i>		
MundiBiopharma	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Oxford Biotherapeutics	Consultant	Self

Entity	Type	Interest Held By
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Pathomiq	Stock	Self
<i>Additional Information:</i>		
Springworks Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Lore Lapeire

Discloser Identifier: 1087960

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Allison Lim

Discloser Identifier: 1087841

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
SpringWorks Therapeutics	Employment	Self
<i>Title:</i> VP Global Disease Area Lead <i>Additional Information:</i>		<i>Position Description:</i> Clinical Development Lead
SpringWorks Therapeutics	Stock	Self
<i>Additional Information:</i>		
SpringWorks Therapeutics	Stock Option	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1014114

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Ayala Pharma	Grant / Contract	Self
<i>Recipient Name:</i> University of Washington <i>Grant / Contract Description:</i> Clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
BioAtla	Grant / Contract	Self
<i>Recipient Name:</i> University of Washington <i>Grant / Contract Description:</i> Clinical trials <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Epizyme, Inc.,	Grant / Contract	Self
<i>Recipient Name:</i> University of Washington <i>Grant / Contract Description:</i> Clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Karyopharm Therapeutics	Grant / Contract	Self
<i>Recipient Name:</i> University of Washington <i>Grant / Contract Description:</i> Clinical trials <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
SpringWorks	Grant / Contract	Self
<i>Recipient Name:</i> University of Washington <i>Grant / Contract Description:</i> Clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes.

- a. Please describe those relationships.

Site-PI for the study reported in the manuscript

2. What is the manuscript title?

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Filomena Mazzeo

Discloser Identifier: 1087962

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Priscilla Merriam

Discloser Identifier: 1087845

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, : A Gamma Secretase Inhibitor for treatment of Desmoid Tumors: a multicenter, randomised versus placebo, phase 3 trial (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Stephanie Moody

Discloser Identifier: 1087421

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, a Gamma-Secretase Inhibitor for Desmoid Tumors

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 738632

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Daiichi Sankyo Company	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Daiichi Sankyo Europe GmbH	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Deciphera Pharmaceuticals Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
EUSA Pharma (US) LLC	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
SynOx Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Tony Philip

Discloser Identifier: 1014454

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Bayer HealthCare Pharmaceuticals Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Daiichi Sankyo Company	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Deciphera Pharmaceuticals Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Joseph Pressey

Discloser Identifier: 890250

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 890248

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Ayala Pharmaceuticals	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trial <i>Additional Information:</i> Site Principal Investigator. Research funding to institution only.		
Bayer HealthCare Pharmaceuticals Inc.	Other	Self
<i>Category:</i> Other <i>Description:</i> Medical Advisory Board <i>Additional Information:</i> One time payment		
C4 Therapeutics	Other	Self
<i>Category:</i> Other <i>Description:</i> Research Funding paid to institution only. <i>Additional Information:</i>		
Epizyme, Inc.,	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaking Engagement and Medical Advisory Board <i>Additional Information:</i>		
Springworks Therapeutics	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trial <i>Additional Information:</i> Site Principle Investigator. Funding paid to institution only. Travel for Investigator Meeting paid by company.		
Springworks Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory Board <i>Additional Information:</i> one time payment		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 878322

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Blueprint Medicines Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Boehringer Ingelheim	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaker fee <i>Additional Information:</i>		
Boehringer Ingelheim	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Deciphera Pharmaceuticals Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Deciphera Pharmaceuticals Inc.	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaker fee <i>Additional Information:</i>		
GlaxoSmithKline	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
PharmaMar	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Entity	Type	Interest Held By
PharmaMar	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaker fee <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 342818

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AADi	Grant / Contract	Other - Institution - Clinical Research Support
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i> Clinical Trial PI		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
AADi	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
AROG	Grant / Contract	Other - Institution - Clinical Research Support
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i> Clinical Trial PI		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Ayala	Grant / Contract	Other - Institution - Clinical Research Support
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i> Clinical Trial PI		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bayer	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory Board <i>Additional Information:</i>		
BioAtla	Grant / Contract	Other - Institution - Clinical Research Support
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i> Clinical Trial PI		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Blueprint Medicines Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisory Board <i>Additional Information:</i>		
Cogent Biosciences	Grant / Contract	Other - Institution - Clinical Research Support
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i> Clinical Trial PI		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Entity	Type	Interest Held By
Daiichi Sankyo Company	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information: Clinical Trial PI		Recipient Type: Institution Grant / Contract Purpose: Research
Deciphera Pharmaceuticals Inc.	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information: Clinical Trial PI		Recipient Type: Institution Grant / Contract Purpose: Research
GlaxoSmithKline	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information: Clinical Trial PI		Recipient Type: Institution Grant / Contract Purpose: Research
Inhibrx	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information: Clinical Trial PI		Recipient Type: Institution Grant / Contract Purpose: Research
Karyopharm Therapeutics	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information: Clinical Trial PI		Recipient Type: Institution Grant / Contract Purpose: Research
NanoCarrier	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information: Clinical Trial PI		Recipient Type: Institution Grant / Contract Purpose: Research
NanoCarrier	Consultant	Self
Category: Consultant Description: Additional Information:		
Oncternal	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information: Clinical Trial PI		Recipient Type: Institution Grant / Contract Purpose: Research
Plexxikon Inc.	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information: Clinical Trial PI		Recipient Type: Institution Grant / Contract Purpose: Research
SpringWorks Therapeutics	Grant / Contract	Other - Institution - Clinical Research Support
Recipient Name: Grant / Contract Description: Additional Information:		Recipient Type: Grant / Contract Purpose:
SpringWorks Therapeutics	Consultant	Self

Entity	Type	Interest Held By
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Tracon	Grant / Contract	Other - Institution - Clinical Research Support
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i> Clinical Trial PI		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Trillium	Grant / Contract	Other - Institution - Clinical Research Support
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i> Clinical Trial PI		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 538314

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Blueprint Medicines Corporation	Consultant	Self
Category: Consultant Description: Additional Information:		
Boehringer Ingelheim	Consultant	Self
Category: Consultant Description: Additional Information:		
Deciphera Pharmaceuticals Inc.	Consultant	Self
Category: Consultant Description: Additional Information:		
Eisai	Consultant	Self
Category: Consultant Description: Additional Information:		
Exelixis Inc.	Consultant	Self
Category: Consultant Description: Additional Information:		
Medpace	Consultant	Self
Category: Consultant Description: Additional Information:		
Merck	Consultant	Self
Category: Consultant Description: Additional Information:		
Servier Pharmaceuticals LLC	Consultant	Self
Category: Consultant Description: Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1087965

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
SpringWorks Therapeutics, Inc	Employment	Self
<i>Title:</i> Chief Development Officer <i>Additional Information:</i>		<i>Position Description:</i> Product Development
SpringWorks Therapeutics, Inc	Fiduciary Officer	Self
<i>Official Title:</i> Chief Development Officer <i>Additional Information:</i>		<i>Position Description:</i> Responsible for drug development
SpringWorks Therapeutics, Inc	Stock	Self
<i>Additional Information:</i>		
SpringWorks Therapeutics, Inc	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 738634

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Aadi	Other	Self
<i>Category:</i> Other <i>Description:</i> Honoraria for participation to a symposium <i>Additional Information:</i>		
Astex Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Bavarian Nordic A/S	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Bayer	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Boehringer Ingelheim	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Daiichi Sankyo Company	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Gentili	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
GlaxoSmithKline	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Entity	Type	Interest Held By
Ikena	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Maxivax	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
pharmamar	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
RainTherapeutic	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Servier Pharmaceuticals LLC	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Springworks	Other	Self
<i>Category:</i> Other <i>Description:</i> research funding to my Institution for clinical study in which I am the Principal Investigator <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for Desmoid Tumors (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 1087958

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, : A Gamma Secretase Inhibitor for treatment of Desmoid Tumors: a multicenter, randomised versus placebo, phase 3 trial (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 992175

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Springworks	Other	Other - Institute
<i>Category:</i> Other <i>Description:</i> advisory board <i>Additional Information:</i> incidental		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, a gamma secretase inhibitor for desmoid tumors (DeFi trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 808773

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
ADRx	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> ADRx working on a cancer project and they are requesting my expertise. (2021) <i>Additional Information:</i></p>		
Apexigen Inc	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> Attended a virtual Advisory Board Meeting in 2020 <i>Additional Information:</i> contract ended</p>		
Ayala Pharmaceuticals	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> 60 minute interview + answering follow up questions. <i>Additional Information:</i> 60 minute interview + answering follow up questions. Ayala Pharmaceuticals is a clinical stage biopharma company developing targeted therapies for rare and aggressive cancers. We are evaluating a new investigational drug for treatment of TGCT. We wish to talk to an expert in the disease and the current treatment options to better understand the unmet needs for another drug on the market.</p>		
Bayer	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> Bayer Virtual Medical Advisory Board on November 30, 2021 <i>Additional Information:</i></p>		
Boehringer Ingelheim	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> Contract to attend Soft Tissue Sarcoma Consultancy Advisory Board series from 2022-2024 <i>Additional Information:</i></p>		
Cytokinetics Inc	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> Advisor shall provide consulting services in the specialized field of medical oncology as requested <i>Additional Information:</i> Advisor shall provide consulting services in the specialized field of medical oncology as requested by Cytokinetics. In this role, the Advisor shall attend and participate in Scientific Advisory Board meeting(s) with Cytokinetics' scientists or management or as otherwise designated by Cytokinetics.</p>		
Daiichi Sankyo Company	Consultant	Self

Entity	Type	Interest Held By
<p>Category: Consultant Description: 2 contracts: 1 for TGCT Advisory Board Meeting 1/25/2021 2nd for Provide expertise Additional Information: The contract expires on 3/31, 2023</p>		
Deciphera Pharmaceuticals, Inc	Consultant	Self
<p>Category: Consultant Description: Attended Deciphera's GIST Expert Advisory Board Additional Information:</p>		
Epizyme, Inc.,	Consultant	Self
<p>Category: Consultant Description: Attended a virtual Advisory board on epitheloid sarcoma. Additional Information:</p>		
Epizyme, Inc.,	Travel	Self
<p>Location(s): Travel to New York to attend TAZVERIK® (tazemetostat) Epitheloid Sarcoma Advisory Board Meeting Purpose: Travel to attend Ad Board Meeting Additional Information:</p>		
GlaxoSmithKline	Grant / Contract	Self
<p>Recipient Name: Brian Van Tine Grant / Contract Description: Research Grant Additional Information:</p> <p style="text-align: right;">Recipient Type: Individual Grant / Contract Purpose: Research</p>		
Merck	Grant / Contract	Self
<p>Recipient Name: Brian Van Tine Grant / Contract Description: Research Grant Additional Information:</p> <p style="text-align: right;">Recipient Type: Individual Grant / Contract Purpose: Research</p>		
Pfizer	Grant / Contract	Self
<p>Recipient Name: Brian Van Tine Grant / Contract Description: Research Grant Additional Information:</p> <p style="text-align: right;">Recipient Type: Individual Grant / Contract Purpose: Research</p>		
Polaris Pharmaceuticals	Other	Self
<p>Category: Other Description: Board Member Additional Information:</p>		
PTC Therapeutics	Consultant	Self
<p>Category: Consultant Description: 2022 Leiomyosarcoma Ad Board Meeting at ASCO Additional Information:</p>		
Tracon Pharmaceuticals	Grant / Contract	Self
<p>Recipient Name: Brian Van Tine Grant / Contract Description: Research Grant Additional Information:</p> <p style="text-align: right;">Recipient Type: Individual Grant / Contract Purpose: Research</p>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

“Nirogacestat: A Gamma-Secretase Inhibitor for Desmoid Tumors (DeFi Trial)”.

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Bruno Vincenzi

Discloser Identifier: 408567

Disclosure Purpose: 22-10140

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat, a Novel Gamma Secretase Inhibitor for Desmoid Tumors

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1087844

Disclosure Purpose: 22-10140

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Adaptimmune	Consultant	Self
Category: Consultant Description: Additional Information:		
Adcendo	Consultant	Self
Category: Consultant Description: Additional Information:		
Boehringer Ingelheim	Consultant	Self
Category: Consultant Description: Additional Information:		
Daiichi Sankyo Company	Consultant	Self
Category: Consultant Description: Additional Information:		
Deciphera Pharmaceuticals Inc.	Consultant	Self
Category: Consultant Description: Additional Information:		
Epizyme, Inc.,	Consultant	Self
Category: Consultant Description: Additional Information:		
Polaris	Consultant	Self
Category: Consultant Description: Additional Information:		
Springworks	Consultant	Self
Category: Consultant Description: Provide expertise regarding diagnosis and clinical treatment of desmoid tumors Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirogacestat: A Gamma Secretase Inhibitor for treatment of Desmoid Tumors: a multicenter, randomised versus placebo, phase 3 trial (DeFi Trial)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.